Chasing improved safety and decreased brain damage for stroke sufferers, Nuvox Pharma LLC is preparing for a fourth quarter start to a phase Ib study of NVX-208 (dodecafluoropentane emulsion), one of multiple oxygen therapeutics the company is advancing.